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Wegener’s granulomatosis or granulomatosis polyangiitis (GPA) is an uncommon chronic systemic vasculitis in children. The aim
of this study was to describe pediatric patients with GPA in Iran. We studied records of all patients with GPA diagnosis who were
referred to all Iranian Pediatric Rheumatology Division from 2002 to 2011. A total of 11 patients (5 females and 6 males) enrolled
in this study. In children less than 15 years old, the prevalence of GPA is 0.6 per million. The mean age of GPA diagnosis was 11
years and average delay diagnosis was 20 months. Mortality rate was 18.1% due to pulmonary vasculitis and infection. The most
common organ system involvement was upper and lower respiratory tract involvement (81.8% and 63.9%, resp.). Other common
manifestations were renal (36.3), skin (27.2%), and eye involvement (18.2%).
1. Introduction
Wegener’s granulomatosis (WG) is a chronic systemic vas-
culitis mainly affecting the upper and lower respiratory
tracts and kidneys that usually involve small to medium-
sized arteries [1]. This condition that also known as granu-
lomatosis polyangiitis (GPA) was described by McBride in
1897 as a midfacial granuloma syndrome, but the complete
picture was described in 1930s [2, 3]. This vasculitis was
characterized by the formation of necrotising granuloma
in the respiratory tracts and necrotizing pauci-immune
glomerulonephritis. The triad of upper and lower respiratory
tract inflammation and renal disease are characteristic for
GPA.
The etiology is unknown, but it is usually associated
with antineutrophil cytoplasmic antibody (ANCA) that was
detected in predominantly cytoplasmic form (cANCA).
The peak incidence of GPA is in the fourth to sixth decades
[4–6] and it is rare in children, so both the American
college of Rheumatology (ACR) classification criteria [7] and
the subsequent Chapel Hill consensus conference (CHCC)
disease definitions [8] are based largely on adult data.
Recently, a consensus committee of pediatric rheumatology
and nephrology experts, under the auspices of the European
League Against Rheumatism (EULAR) and the Pediatric
Rheumatology European Society (PReS), proposed a system
of classification for vasculitis that took into account existing
pediatric knowledge and experience [9].
At onset, nonspecific complaints of fever, malaise, fatigue,
and weight loss are very common. A large majority of
children with GPA present with multiple organ involvement.
There is no comprehensive study on GPA in Iran. So, the
aim of this study was to describe pediatric patients with GPA
from all pediatrics rheumatology divisions of Iran to analyse
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the variety of clinical manifestations seen and to compare the
data with other published series.
2. Material and Methods
We studied records of all patients with GPA diagnosis
who were referred to all Iranian Pediatric Rheumatology
Division from 2002 to 2011. Data included age, gender, age
of onset, delay in diagnosis, clinical features before diagnosis,
and clinical signs observed at diagnosis, laboratory and
histopathological findings, imaging findings, and response to
treatment. We used the EULAR/PRES criteria [9] to confirm
the diagnosis. The patient was considered to have GPA when
three of the following six criteria were present:
(1) nasal, oral inflammation, or sinus inflammation;
(2) abnormal chest radiograph or chest CT scan;
(3) abnormal urinalysis including signification protein-
uria;
(4) granulomatous inflammation on biopsy or necrotiz-
ing pauci-immune GN on biopsy;
(5) subglottic, tracheal, or endobronchial stenosis
(6) PR3 ANCA or cANCA staining.
This study was approved by local ethical committee of
Children’s Medical Center, pediatric center of excellence in
Iran.
3. Result
During 10 years of study, 11 patients with GPA diagnosis were
admitted in all Iranian Pediatric Rheumatology Division.
Five patients were female (45.4) and 6 male (54.5) with
male/female ratio of 1.2 : 1. During this period, almost one
third of the population (17,680,000) is less than 15 years old.
The prevalence of GPA was 0.6 per million. The mean age
at primary symptom onset was 9.7 (range 4 to 15) years and
the mean age of GPA diagnosis was 11 (range 6 to 15) years.
The average delay diagnosis was 20 months; this index was 6
months and 23 month in died and alive patients, respectively.
Ten of 11 children fulfilled EULAR/PRES criteria and one
patient was diagnosed based on the clinical picture typical
of the disease. The mean duration of follow-up for living
patients was 6.4 years. Two patients died (mortality rate
18.1%) including a female patient after 2 weeks of diagnosis
with pulmonary hemorrhage and another male patient after
12 months of diagnosis with proptosis and orbital pseudotu-
mour. Final diagnosis for the last patient was disseminated
fungal infection after retroorbital granulomatousmass due to
fungal infection.
Initial clinical manifestations of our patients are summa-
rized in Table 1.
At onset, fatigue as a nonspecific complaintwas very com-
mon (81.8%). The most common organ system involvement
was upper respiratory tract (81.8%) and lower respiratory
tract involvement was seen in 63.9%. Six children (54.4%)
had abnormal imaging in chest X-ray or chest CT-scan. Renal
involvement was observed in 4 children (36.3).
Table 1: Clinical manifestations of patients with Wegener granulo-
matosis.
Clinical feature Number Percentage
Nonspecific complaints
Malaise, fatigue 9 81.8
Fever 2 18.8
Weight loss 2 18.8
Lower respiratory tract (𝑛 = 7)
Hemoptysis 2 18.1
Pleural effusion 1 9
Shortness of breath 2 18.1
Abnormal imaging 6 54.4
Upper respiratory tract (𝑛 = 9)
Sinusitis 8 72.7
Otitis 3 27.2
Saddle nose 2 18.1
Renal (𝑛 = 4)
Microscopic hematuria 4 36.3
Nephritic syndrome 1 9
Eyes 2 18.8
Skin 3 27.2
Gastrointestinal 3 27.2
Musculoskeletal
Arthritis in knee and ankle 3 27.2
Nervous system
Severe headache and seizure 1 9
Vasculitis 1 9
Venous thrombosis 1 9
The eyes involvement was seen in 2 patients, one of
them had proptosis due to a retroorbital granulomatousmass
(showed on biopsy), and the other patient had periorbital
cellulitis.
Skin involvement was observed in 3 children. Two
patients had necrotic lesions that one of them presented
with pyoderma gangrenosum. In skin biopsy, they showed
necrotizing granuloma and leukocytoclastic vasculitis and
3rd one had a nonspecific rash. Gastrointestinal involvement
was found in 3 patients that one of them showed follicular
gastritis in biopsy.
LaboratoryMarkers. Cytoplasmic antineutrophil cytoplasmic
autoantibodies (cANCA) or proteinase-3 (PR3)-ANCA was
positive in all patients and p-ANCA (MPO) was positive in 2
patients. ANA was positive just in one patient. Two patients
had thrombocytopenia (67000 and 95000) without active
bleeding. Antiplatelet antibody was negative in thrombocy-
topenic patients.
4. Discussion
The aim of this study was a comprehensive report on GPA in
Iranian children. The peak incidence of GPA is in the fourth
to sixth decades [4–6] and it is rare in children and the main
reports on WG are in adult patients. Mortality rate in our
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study was 18% and it occurred during 1 year after diagnosis.
This rate was 20.8% and 27% in other studies [10, 11]. Luqmani
et al. reported higher mortality rate during the first year after
diagnosis [10]. Similar to Luqmani et al study, the causes
of mortality in our study were infection and vasculitis, but
unlike their findings anyone of our patients didn’t have renal
failure [10]. Some factors have been studied as predictors of
mortality in GPA. Higher age (>52 y) and renal involvement
have been a positive effect on mortality rate, while the ENT
involvement has had an association with a longer survival
[10, 11].
Onset ofGPAbefore 10 years old is uncommon.Themean
age at diagnosis in our group was 11 years (rang 4 to 15) that
was older than reported by Belostotsky et al. (6 years) [12].
Themean age at GPAdiagnosis was reported 14.2 years (range
4 to 17) by Cabral et al. [13].
In our study, male/female ratio was similar to that
reported by Stegmayr et al. [14] and adult literature [15–17],
but some studies reported a significant female predominance
in their patients [12, 18–21].
Similar to other studies, fatigue andmalaisewere themost
common symptom in our patients [21, 22]. Respiratory tract
is the most common involvement in GPA. In our studies,
upper and lower respiratory tract was affected in 81.1% and
63.3% patients, respectively. This rate was very different in
other studies. Chinese patients had 51.9% and 77.8% [23]
and Rodrigues et al. [20] reported 64% and 36% upper and
lower respiratory tract involvement, respectively. Sometimes
respiratory tract involvement needs surgical intervention.
Eustaquio et al. reported 25% respiratory tract involvement
with airway lesions and surgical interventions [17].
In Belostotsky study renal involvement was 3 times in
children after 5 years in comparison to less than 5 years
old [12]. Renal involvement has been reported very different
in children between 53 and 88% [12, 23] and this rate was
less frequent than in adult (85%) [15]. It seems that renal
involvement is more frequent in adult than in children. In
addition, early diagnosis and treatmentmay prevent nephritis
and progress to end stage renal disease. Similar to Cabral
report, in our group microscopic hematuria was the most
common involvement [13].
Eyes were affected in 2 of our patients (18.8%). This rate
was very different from 25 to 60% in other studies [12, 18,
20, 21]. In Chinese series ophthalmic involvement was more
frequent in p-ANCA positive patients [23]. Skin lesion is
uncommon symptom in GPA. In our case series the rate of
skin involvement was 27.2%. In other study this rate was 11–
48% [20–22].
5. Conclusion
GPA is a rare rheumatologic disorder in Iranian childrenwith
prevalence less than 1 per million children.Themortality rate
was 18.1% in our study. GPA should be considered as a rare
diagnosis in children with chronic respiratory involvement
in concomitant with other organ involvement such as eye or
renal involvement.
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